Approximately 2,500 patients in the United States die every year on the liver transplant waiting list before a donor liver becomes available.1 Increasing the number of organs available for transplantation, while reducing post-transplantation complications and shortening the length of hospital stay, are important clinical goals to improve patient outcomes.
|Patients at start of year||14,956||15,360||15,428|
|Patients added during year||10,349||10,359||10,143|
|Patients removed during year||9,925||10,272||10281|
|Patinets at end of year||15,380||15,447||15,290|
|Removal reason||0.068 g||0.5||0.5|
|Deceased donor transplant||5,450||5,539||5,468|
|Living donor transplant||209||187||192|
|Patient refused transplant||53||60||73|
|Improved,transplant not needed||552||541||644|
|Too sick to transplant||362||482||815|
|peakserum AST||1154 IU/mL||3339 IU/mL||0.011|
|Peakserum ALT||560 IU/mL||1358 IU/mL||0.044|
A controlled clinical feasibility study at Columbia University Medical Center/New York Presbyterian Hospital using a prototype LifePort Liver Transporter system found 50 percent fewer patients had biliary complications with LifePort-perfused livers. Early allograft dysfunction was seen in 25 percent of static cold stored livers compared with 5 percent of LifePort-perfused livers (p = 0.08).2Additionally, patients receiving LifePort perfused livers had a significantly lower length of hospital stay than patients with static cold stored livers (10.9 ± 4.7 days vs. 15.3 ± 4.9 days; p = 0.006).
A second controlled study investigated hypothermic machine preservation versus static cold storage of expanded criteria livers rejected by the originating UNOS region.3 During 12-months post transplantation there were significantly fewer biliary complications in the perfused group (4 vs. 13, respectively; p = 0.016), and early allograft dysfunction rates were also lower (19% vs. 30%). Mean hospital stay was also significantly shorter in the perfused group (13.6 vs. 21.1 days). The results suggest that hypothermic machine perfusion (HMP) of livers is safe and allows for transplantation of expanded criteria livers deemed untransplantable by multiple centers. Study investigators concluded that HMP has the potential to increase the donor pool and the availability of livers for patients on the waiting list.
LifePort Liver Transporter is in the process of securing US and European regulatory registrations. Its design, engineering and performance capabilities are based upon the LifePort prototype system used in the Columbia University Medical Center/ New York Presbyterian Hospital, and the proven technology platform of the market leading LifePort Kidney Transporter.
LifePort Liver Transporter is designed to deliver precision controlled perfusion of the hepatic artery and portal vein. Hypothermic perfusion is supported by redundant preservation systems for safety – dynamic perfusion plus static cold storage.
The clear programmable interface displays key data that track real-time organ perfusion status, patient ID number and blood type, cross clamp and total infusion time, perfusate temperature, hepatic and portal flow and pressure and total flow.
LifePort Liver Transporter's lid folds out to provide an optional work surface for crowded OR suites. The work surfaces lids are hinged for easy removal and storage.
The height-adjustable fold-flat cart seamlessly docks with LifePort Liver Transporter, and is designed to provide optimal surgeon comfort and optical range.
Watch Dr. James V. Guarrera, Associate Professor of Surgery, Surgical Director of Adult Liver Transplantation, Columbia University Medical Center/New York Presbyterian Hospital, NY, USA, discuss his experience with hypothermic machine perfusion of livers for clinical transplantation
Full Summary of the Clinical Experience for LifePort Liver Transporter › Caution—Investigational Device. Limited by Federal law to investigational use. Registrations underway in US and EU.